Introduction
Angiogenesis, the growth of new blood vessels, is required for the normal development and differentiation of the vascular tree as well as for organ repair after injury. However, if not properly controlled, angiogenesis can also represent a significant pathogenic component of tumor growth and metastasis, rheumatoid arthritis, or retinopathies (1, 2) . Several growth 1 . Abbreviations used in this paper: a and bFGF, acidic and basis fibroblast growth factor; EGF, epidermal growth factor; PD-ECGF, plateletderived-endothelial cell growth factor; PDGF, platelet-derived growth factor; rhVEGF, recombinant human vascular endothelial growth factor; TGF, transforming growth factor, TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. ing growth factors (TGFs) a and (3, tumor necrosis factor a (TNFa), and angiogenin, can stimulate angiogenesis in vivo. Until recently, however, only the acidic and basic fibroblast growth factors (aFGF and bFGF) and platelet-derived endothelial cell growth factor (PD-ECGF) had been shown to act directly on endothelial cells to induce their proliferation (3) (4) (5) . Nevertheless, the role ofthese three factors in the maintenance of the endothelium is not clear. The fibroblast growth factors are widely distributed and potently stimulate the proliferation of endothelial cells and other cell types. However, both FGFs and PD-ECGF lack a signal sequence and may be available to the endothelium only after trauma or cell death (6, 7) .
Vascular endothelial growth factor (VEGF) is a dimeric heparin-binding protein with a molecular weight of -45,000 that was isolated and purified from media conditioned by bovine pituitary folliculostellate cells (8) . VEGF-like factors have also been identified from media conditioned by various normal and transformed cell types (i.e., [9] [10] [11] [12] . The amino acid sequence of VEGF is highly conserved across species and has homology with the A and B chains of platelet-derived growth factor (PDGF).
Several lines of evidence indicate that VEGF might have a specific role in the development and maintenance of blood vessels. VEGF exerts a potent mitogenic effect on vascular endothelial cells derived from both small and large vessels, while no proliferative effects are seen on a variety of other cell types in vitro (8) . Also, VEGF can be secreted by intact cells, because its NH2 terminus is preceded by a typical signal sequence ( 13) . Further evidence of a physiological role for VEGF has been suggested by in situ hybridization studies that have shown that the VEGF mRNA is widely distributed in vascularized organs and expressed at high levels in areas ofactive vascular proliferation. In the ovary, for example, a temporal relationship exists between VEGF mRNA expression and growth ofcapillary vessels in the corpora lutea (14, 15) .
Recent studies have shown that 125I-VEGF can bind reversibly and with high affinity to sites on a variety of cultured endothelial cells (16) (17) (18) and also to sites on several transformed cell types that are not stimulated to proliferate by VEGF (19) . However, cells in culture may exhibit different binding characteristics than in vivo, as many phenotypic and functional characteristics can be modified by conditions within the surrounding cellular environment (20) . Therefore, to determine the distribution of cells that might respond to VEGF within the context of intact tissues, binding to tissue sections from adult rats was performed with biologically active, iodinated recombinant human VEGF ('25I-rhVEGF). Quantitative autoradiography was used to examine the binding kinetics and simultaneously localize binding sites at both macroscopic and microscopic levels (21 IN) , and the concentration was approximated independently ofbiological activity by TCA precipitation. Nonprecipitable 125I accounted for < 5% of the final preparation.
The radioligand was tested for its ability to promote growth ofadrenal cortex capillary endothelial cells (23) . Cells were plated at a density of 600/well in microtiter plates in the presence of various concentrations of rhVEGF or '251-rhVEGF. After 5 or 6 d cell densities were determined by a colorimetric acid phosphatase reaction (24) .
Binding studies. Individual tissues were obtained from 10 adult male rats (Sprague-Dawley; 200-240 g; an additional 3 female rats were used for descriptive analysis of binding in ovary). After the rats were asphyxiated in C02, fresh tissues were frozen in isopentane at -15°C and were stored for up to 2 mo at -70°C. Frozen sections were cut at 12 Am, thaw mounted onto gelatin-coated slides, and stored in air-tight boxes at -70°C for no more than 4 mo. Fresh-frozen wholebody sections were prepared from 3 additional male rats as previously described (25) . Sagittal sections of 25 Mm (LKB PMV 2250 Cryomicrotome; LKB Instruments, Inc., Gaithersburg, MD) were collected from 6-10 levels, mounted onto precooled cellophane tape and stored in airtight plastic bags at -70°C for up to 2 mo.
After thawing, whole-body or tissue sections were preincubated for 3 h in DME supplemented with 10% FCS (Gibco Laboratories, Grand Island, NY), 25 mM Hepes, 0.5 mM MgCl2, 4 Ag/ml leupeptin, and 5 nM PMSF (reagents from Sigma Chemical Co., St. Louis, MO; all incubations were done at 22°C). The preincubation buffer was then removed and the sections were covered by a droplet of the same buffer containing 10-420 pM '251-rhVEGF. Adjacent sections were incubated in the same concentration of 1251-rhVEGF with the addition of 2-2.5 nM rhVEGF to define nonspecific binding. Competition of binding in the presence of 1 pM-500 nM rhVEGF, 20 pM-100 nM PDGF, EGF or bFGF, or 100 pM-100 MM heparin was also examined (PDGF, EGF, and bFGF from Amgen Biologicals, Thousand Oaks, CA; heparin sodium salt from Sigma: 180 USP/mg). After a 34-h incubation in a humidified chamber, all slides and sections were rinsed for 2 s in PBS containing 200 mM NaCl and 0.5 mM MgCI2, and then washed twice in the same buffer (10 min each). Slide-mounted sections were fixed for 10 min in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), rinsed for 2-5 s in dH2O, and dried quickly with a stream of room-temperature air.
Bindingcharacteristicswere evaluatedby quantitative autoradiography on kidney, brain, pancreas, or heart sections from 4-6 rats. Kinetics were determined using equilibrium saturation analysis (kidney and brain), association and dissociation kinetics (kidney), and competition analysis (kidney and brain) (26) . Specificity competition studies were performed on sections from all four regions. For analysis, the dried sections and 1251 standards (Amersham Corp., Arlington Heights, IL) were apposed to x-ray film (3H-Hyperfilm; Amersham) at 220C for 3-12 d. The films were developed in Kodak D-19 (Eastman Kodak Co., Rochester, NY) and then analyzed with an RAS 3000 system (Amersham) by scaling measured optical density values to known standard activities using established methods (27, 28) . Estimates of EC50 and ICm values for binding were determined by iterative nonlinear regression analysis using a four-parameter fit (29) . Scatchard analysis was performed using a modification of the computerized analysis program LIGAND (30 (31, 32) . The sections were washed for 10 min in PBS containing 500 mM NaCl (high salt buffer) and then for 30 min in 0.03% H202. After preincubation for 1 h in 3% normal goat serum (Vector Laboratories, Inc., Burlingame, CA) sections were incubated in rabbit anti-human Factor VIII-related antigen (BioGenex Laboratories, San Ramon, CA; 1:50) for 15 h at 40C. The primary antibody was detected using the avidin-biotin peroxidase system (ABC; Vector Labs) with diaminobenzidine as the chromogen (33) . The specificity of staining was confirmed by positive anatomical localization and by the lack of staining when either the primary or secondary antibodies were replaced by normal serum. After exposure to films or immunocytochemical staining, the glass slides were dipped for 3 s in Kodak NTB2 liquid emulsion (International Biotech, New Haven, CT; 1:1 with dH2O). The slides were dried overnight and stored, with desiccant, at 4VC for 2-5 wk. The slides were developed with Kodak D-19 and counterstained with hematoxylin and eosin. Purified rhVEGF competed for binding with the radioligand with equivalent potency (IC50 for 75 pM 1251-rhVEGF = 58-70 pM rhVEGF in brain, kidney, and pancreas sections) (Fig. 3 A) . In contrast, the density of binding sites was not affected by the addition of up to 100 nM of PDGF, EGF, or bFGF. Likewise, no decrease in total or nonspecific binding was observed in brain, pancreas, or heart sections when -100 pM-100 ,M heparin was added to the incubation medium (Fig. 3 B) .
Distribution ofbinding sites. Incubation ofwhole body sections in 70-80 pM '25I-rhVEGF revealed displaceable binding in all organs, with the highest levels in brain and spinal cord, adrenal cortex, glandular stomach, lung, spleen, and pancreas (Fig. 4) . In these organs, the binding was displaced by 70-90% with the addition of 2.5 nM rhVEGF to the incubation medium. Throughout the sections, specific binding was heterogeneously distributed in a manner consistent with the known vascular pattern of most tissues (35, 36) .
The distribution of 125I-rhVEGF binding sites was then examined with higher resolution by emulsion autoradiography of slide-mounted sections. Binding and immunocytochemical staining with antiserum to Factor VIII-related antigen were performed on the same sections ( Fig. 5-8 ).
In the central nervous system, 125I-rhVEGF binding sites were associated with Factor VIII immunoreactivity in arteries, veins, and microvessels ( Fig. 5 A-D) . The density of binding was greatest in the gray matter ofthe brain and spinal cord (see also Table I ). In the cerebral cortex, the binding pattern followed the distribution of penetrating vessels extending from the outer meninges toward the deeper laminae. Displaceable binding was also associated with the meninges and the large vessels on the surface ofthe brain and spinal cord, and was seen along vascular elements in the choroid plexus. No binding was seen along the ependyma ofthe ventricles. Examination ofpituitary sections revealed binding in the pars distalis and pars nervosa, while essentially no binding was seen in the poorly vascularized pars intermedia.
Heart sections ( Fig. 6 ) exhibited a diffuse pattern of displaceable binding sites throughout the atrial and ventricular myocardium. At higher magnification, this binding was colocalized with Factor VIII immunoreactive cells lining microvessels and larger coronary vessels. The most striking region was the intense binding distributed along the endothelial lining of the heart valves and the aorta, and pulmonary artery and vein. Binding was also associated with the vessels within the tunica adventitia supplying the aortic wall (vasa vasorum). In contrast, displaceable binding to smooth muscle cells in the media was not evident (Fig. 6, E and F mined by a linear fit using means at each time point, and are reported for three regions of kidney in Table I. localized. In contrast, binding and Factor VIII-like staining were both distinctly absent along the epithelial lining of the bronchi.
In the liver and pancreas, binding and Factor VIII immunoreactivity were colocalized along the lining of larger vessels, including the hepatic vein, hepatic artery, and portal branches (Fig. 5, E and F 
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In contrast with most organs and tissues in adult animals, where the endothelium is quiescent, follicular development in the ovary is accompanied by an active cycle of angiogenesis during luteal development and vascular degeneration during its regression (37) . The binding patterns observed in ovary sections from normally cycling rats reflected this dynamic vascular environment (Fig. 8) . In the central medulla region, displaceable binding was found in association with numerous blood vessels. In secondary and mature follicles, binding was absent within the granulosa cell region. Binding was evident in the lining of vessels surrounding the theca and throughout the mature corpus luteum. Finally, in degenerating corpora lutea, binding of '25I-rhVEGF was limited to the periphery and no binding sites were found within the central region of lutein cell degeneration.
Discussion
The identification ofbinding sites for growth factors is a crucial step in understanding the biological response of cells and tissues to these factors. These studies reveal both the kinetic characteristics and distribution of binding sites, and also suggest a physiological role for VEGF. '25I-rhVEGF binding sites are distributed throughout all the tissues of the adult rat in a pattern that reflects the distinct vascularization of each organ. Quantitative autoradiographic analysis demonstrates that 12511 rhVEGF binds to these mature tissues with an affinity in the 10-50-pM range, consistent with the specificity and potency of VEGF both in vivo and in vitro (8) (9) (10) (11) (12) (13) Target-cell specificity is likely to be an important characteristic ofa factor that contributes to the maintenance ofthe endothelium or blood vessel growth in normal conditions. Perhaps not surprisingly, VEGF binding sites are found on the growing vessels within the ovary. However, VEGF binding sites are also tonically expressed in vessels that are not actively involved in angiogenesis. The uniform presence ofVEGF binding sites also parallels the continual expression of VEGF mRNA in most adult tissues as detected by in situ hybridization studies. Previous studies have shown that the mature VEGF protein can be secreted and would thus be available to the surrounding endothelial cells in physiological conditions. Therefore, in addition to initiating new vessel growth, VEGF appears to be available for maintaining the vascular endothelium.
An especially high density ofbinding sites is found in association with the endothelial lining of the heart valves. These highly dynamic structures are constantly subjected to the shear forces of blood flow under high pressures. Furthermore, the integrity of the endothelial lining is essential to prevent such conditions as thrombosis or endocarditis (39, 40) . The presence of high affinity binding sites in these regions emphasizes that VEGF may be important for continual repair and maintenance in regions that are susceptible to endothelial erosion.
VEGF is now known to belong to a family of polypeptides with different molecular and biological characteristics. By alternative splicing of mRNA, human VEGF can exist in four molecular forms having 121, 165, 189, or 206 amino acids, of which the 165 amino acid is the most abundant (13, 41) . The biological significance ofthese different forms is not yet understood. The 165 and 121 amino acid species are both efficiently secreted by cells, as assessed by immunoprecipitation studies and bioactivity in the conditioned medium oftransfected cells (41) . Therefore, these forms of VEGF are most likely to be available in physiological conditions. In contrast to VEGF121 and VEGF165, the two longer forms of VEGF appear to be mostly cell associated, despite the presence ofan identical signal sequence. The information required to remain cell associated appears to be encoded within an insertion of 24 amino acids. This region is highly enriched in basic residues, and is homologous to exon 6 of PDGF-A (42). The sequence of VEGF189 is the same as that reported for human vascular permeability factor (VPF), a protein identified from tumor cell lines on the basis of its ability to induce vascular leakage and protein extravasation (43, 44) . Those findings suggested that the expression ofVPF by tumors could be responsible for the abnormal permeability properties of tumor vessels and the accumulation ofascites fluid. Recent observations indicate that all four molecular species of VEGF can promote dye extravasation when applied in a guinea pig skin permeability assay (41) . However, the present findings show that in physiological conditions, the more abundant form of VEGF (VEGF165) is probably not responsible for regulating permeabil-252 L. B. Jakeman, J. Winer, G. L. Bennett, C. A. Altar, and N. Ferrara ity and protein extravasation directly. '251-rhVEGF binding sites are found in permeable capillaries (i.e., kidney glomeruli) as well as in capillaries with tight junctions (i.e., brain). Likewise, VEGF mRNA is also consistently detected around both types of microvessels. Future studies, comparing the binding characteristics and the biological activities of these proteins may help to determine if the four molecular species can act at the same, or related, receptors in normal or transformed cells and tissues.
